PRESS RELEASES

August 13, 2020

4D Molecular Therapeutics Receives FDA Fast Track Designation for 4D-310 Gene Therapy for Treatment of Fabry Disease

Emeryville, CA – August 13, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...

July 27, 2020

4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia

Emeryville, CA – July 27, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the first patient has been dosed in the Phase 1 clinical trial ...

June 17, 2020

4D Molecular Therapeutics Announces New Agreement with Cystic Fibrosis Foundation

EMERYVILLE, CA. – June 17, 2020 – 4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, today announced a new agreement with Cystic Fibrosis Foundation (CF Foundation) to develop precision ...